DrugsControl Media Services

News Detail

US FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings (27-12-2017)

Maryland, 19 Dec 2017: The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including......
View Details

Source : US FDA Safety Anouncement

Related News